note -the following-the portion in bold- is 1 of many evidences that internal flat pack sales are growing.
One poster noted many months ago that the CEO himself was packing orders,part of an effort to avoid the usual toxic financing that destroys so many companies.
Many pennies dont even have a product, let alone game changing products.
Fewer still have any revenue.
Far fewer still achieve net income,one of the key turning points NNLX is trying to achieve via increasing flat pack sales,cutting expenses, 3 grant proposals,the game changing move announced July 12,2017 to sell, license or partner re the flat pack patent in eu etc geographic markets.
If even one of the possibly dozen interested parties in the many countries interested in NNLX patented flat pack partner in one of several possible manners,that alone could be a game changer for NNLX,especially if it is a company,as I would expect it to be,with established distribution channels. NNLX's problem with the flat pack is breaking through large companies extant distribution channels,even though flat pack sales increased over 400% yoy in the last posted financials.
If any one of the 3 grant proposals succeed or an agreement is made with any one of a probable dozen interested parties,that could be the breakthrough NNLX needs.
In a development company,the key is to commercialize the products.
It wasn't til April 2018 that NNLX finished a many year process necessary to make it possible to commercialize the product in the eu.
Thus, in the last year the company has made a conscious effort to commercialize even as the steps do so continued.
This transition to commercialization is what investors look for so net revenue can be achieved and thus fuel internal growth without the need for dilutive measures.
Once substantial internal growth is achieved and NNLX upgrades to current pink or better so the current static limited investment pool can grow dramatically and eliminate 3 major reasons why shorters target otc 'no info' companies, the pps should skyrocket.
The pps jumped many times over a year ago without the benefit of these things.
In my recent posts I forget to mention the following 3rd update in April - 3 updates in April
April 19,2018
Update On Petri FlatPack International Patent Status
Pursuant to NanoLogix' International Patent Offering
NanoLogix is pleased to announce payment yesterday (18 April 2018) of annuities for the FlatPack petri plate extended-life packaging patent in the EU and other granting countries. These annuity payments were made possible through a long time shareholder's efforts and the resulting receipt of funds by the Company from a new investor. The importance of the annuity payments cannot be overstated for the development of Nanologix --- sale and/or licensing of the FlatPack Patents internationally is projected to provide funding for the Company's expansion of agar-filled petri plate production in the USA and to complete development and pursue marketing of both the N-Assay modified ELISA rapid bacteria diagnostic test and its associated Pre-test.
Without the potential to monetize the international patent assets the Company's development would depend upon domestic organic growth only, a process that while steady, would not meet NanoLogix' needs for rapid expansion.
One poster noted many months ago that the CEO himself was packing orders,part of an effort to avoid the usual toxic financing that destroys so many companies.
Many pennies dont even have a product, let alone game changing products.
Fewer still have any revenue.
Far fewer still achieve net income,one of the key turning points NNLX is trying to achieve via increasing flat pack sales,cutting expenses, 3 grant proposals,the game changing move announced July 12,2017 to sell, license or partner re the flat pack patent in eu etc geographic markets.
If even one of the possibly dozen interested parties in the many countries interested in NNLX patented flat pack partner in one of several possible manners,that alone could be a game changer for NNLX,especially if it is a company,as I would expect it to be,with established distribution channels. NNLX's problem with the flat pack is breaking through large companies extant distribution channels,even though flat pack sales increased over 400% yoy in the last posted financials.
If any one of the 3 grant proposals succeed or an agreement is made with any one of a probable dozen interested parties,that could be the breakthrough NNLX needs.
In a development company,the key is to commercialize the products.
It wasn't til April 2018 that NNLX finished a many year process necessary to make it possible to commercialize the product in the eu.
Thus, in the last year the company has made a conscious effort to commercialize even as the steps do so continued.
This transition to commercialization is what investors look for so net revenue can be achieved and thus fuel internal growth without the need for dilutive measures.
Once substantial internal growth is achieved and NNLX upgrades to current pink or better so the current static limited investment pool can grow dramatically and eliminate 3 major reasons why shorters target otc 'no info' companies, the pps should skyrocket.
The pps jumped many times over a year ago without the benefit of these things.
In my recent posts I forget to mention the following 3rd update in April - 3 updates in April
April 19,2018
Update On Petri FlatPack International Patent Status
Pursuant to NanoLogix' International Patent Offering
NanoLogix is pleased to announce payment yesterday (18 April 2018) of annuities for the FlatPack petri plate extended-life packaging patent in the EU and other granting countries. These annuity payments were made possible through a long time shareholder's efforts and the resulting receipt of funds by the Company from a new investor. The importance of the annuity payments cannot be overstated for the development of Nanologix --- sale and/or licensing of the FlatPack Patents internationally is projected to provide funding for the Company's expansion of agar-filled petri plate production in the USA and to complete development and pursue marketing of both the N-Assay modified ELISA rapid bacteria diagnostic test and its associated Pre-test.
Without the potential to monetize the international patent assets the Company's development would depend upon domestic organic growth only, a process that while steady, would not meet NanoLogix' needs for rapid expansion.
2
